JOTHAM W. COE Synthetic and Medicinal Chemistry
EDUCATION · Ph.D. - Synthetic Organic Chemistry
EXPERIENCE · BioPharmaWorks - Vice President, 2018 →present · Pfizer - Research Fellow, 1988 → 2018, Oncology, Neuroscience, Immunology, Medicinal Sciences.
EXPERTISE · Synthetic Chemistry, Medicinal, and Structure-based drug design, Outsourcing. The inventor of Chantix™ / Champix™ (varenicline). 2010 “Heroes of Chemistry” Award for the discovery of varenicline (Chantix) and the 2015 Award for Creative Invention, both from the American Chemical Society. Over 100 patents and scientific publications.
BIO
Jotham Coe is a medicinal chemist with 30 years of experience in discovery at Pfizer Inc. His interest in organic chemistry was piqued as an undergraduate at Harvard where he worked with William von E. Doering and later with William R. Roush at MIT where he received his Ph.D. in synthetic organic chemistry. After brief postdoctoral work with BIll Roush at Indiana University, he joined Pfizer. A skilled synthetic and medicinal chemist, he has pharmaceutical experience in Neuroscience, Oncology, Inflammation, and Immunology therapeutic areas as well as the Synthetic and Medicinal Technology area. He has extensive experience in the use of design, modeling and conformational analysis for interpretation of compound interactions to optimize compounds and scaffold series through multi-step syntheses of complex organic molecules (milligram to kilogram scale). Jotham worked closely with Brian O'Neill and Hans Rollema and a close-knit neuroscience team leading to the discovery of varenicline, (Chantix, Champix), an aid to smoking cessation treatment. In recognition, he received the 2010 ACS Heroes of Chemistry Award and 2015 ACS Award for Creative Invention. Jotham was involved in the identification of multiple medicinal candidates over his career in Neuroscience and Inflammation working closely with his collaborators and outsourcing teams. Jotham has over 100 publications and patents and has given numerous presentations in synthesis and medicinal chemistry around the world. Jotham now works with BioTech collaborators at BioPharmaWorks to progress programs focused on aging, oncology, inflammation, rare disease and neuroscience therapeutics.